This bill aims to ban a common practice in the prescription drug industry where drug manufacturers give rebates and discounts to insurance companies and pharmacy benefit managers (the companies that handle drug benefits for health plans). Right now, these rebates are supposed to be passed on to patients, but often they're kept by middlemen, which can actually drive up drug prices for consumers.

The bill would make it illegal for drug manufacturers to offer these hidden rebates to health insurance plans, pharmacy benefit managers, or Medicare/Medicaid programs starting January 1, 2025. It applies to all types of health coverage—employer plans, individual insurance, Medicare Part D, and more. The law specifically targets rebates that are meant to influence which drugs insurance companies prefer to cover (called "formulary tier placement"), which is a major way manufacturers currently compete.

The goal is to simplify the drug pricing system and potentially lower what patients actually pay at the pharmacy. By eliminating these behind-the-scenes deals, the bill's supporters believe drug prices will be more transparent and competitive. However, critics worry it could reduce negotiating power that insurers currently use to get better prices from manufacturers, potentially raising costs instead. The changes would affect anyone with health insurance, Medicare, or Medicaid coverage, since it impacts how their drug benefits are managed and priced.

Ending the Prescription Drug Kickback Act of 2023

Hawley, Josh

Ending the Prescription Drug Kickback Act of 2023 This bill generally prohibits prescription drug manufacturers from providing rebates to pharmacy benefit managers (PBMs) or private health insurance plans. Specifically, the bill eliminates the safe harbor for rebates, or other payments, provided to PBMs that are intended to influence the applicable cost-sharing tier of the drug (e.g., placing the drug in a more favorable formulary tier). The bill further prohibits health insurance plans from receiving such rebates with respect to a prescription drug covered by the plan. Plans also must ensure PBMs do not receive any such rebates.